Table 3 Baseline characteristics of all OptiTrain participants and completers 5-years post-baseline.
All participants tested at baseline n = 206 | Completers 5 years post-baseline n = 95 | |||||
|---|---|---|---|---|---|---|
RT-HIIT n = 74 | AT-HIIT n = 72 | UC n = 60 | RT-HIIT n = 35 | AT-HIIT n = 36 | UC n = 24 | |
Age (years) | 52.7 ± 10.3 | 54.4 ± 10.3 | 52.6 ± 10.2 | 53.5 ± 10.4 | 56.1 ± 8.3 | 52.8 ± 9.4 |
Body mass (kg) | 68.7 ± 11.3 | 67.7 ± 13.0 | 69.1 ± 11.0 | 68.1 ± 9.5 | 67.2 ± 11.7 | 69.6 ± 9.6 |
BMI (kg/m2) | 25.1 ± 4.3 | 24.8 ± 4.4 | 24.6 ± 4.8 | 24.7 ± 3.7 | 24.7 ± 3.9 | 24.7 ± 4.3 |
MVPA (min/week) | 79.8 ± 31.7 | 70.4 ± 28.9 | 70.0 ± 36.4 | 90.8 ± 34.9 | 76.1 ± 26.0 | 71.6 ± 38.6 |
SED (min/day) | 523.3 ± 112.7 | 543.6 ± 109.0 | 552.8 ± 101.9 | 535.3 ± 103.0 | 562.4 ± 107.7 | 576.6 ± 87.9 |
Married or partnered | 60.6 | 59.7 | 69.5 | 60.0 | 58.3 | 79.2 |
University completed | 67.6 | 64.7 | 66.0 | 77.1 | 66.7 | 54.2 |
Current smoker | 4.3 | 5.9 | 5.2 | 2.9 | 2.8 | 4.2 |
Postmenopausal | 51.4 | 63.9 | 61.7 | 54.3 | 77.8 | 54.2 |
Tumour profile | ||||||
Triple negative | 14.9 | 11.0 | 16.7 | 5.7 | 16.7 | 16.7 |
HER2 + , ER + / − | 21.6 | 30.2 | 20.0 | 25.7 | 33.4 | 20.9 |
HER2 − , ER + | 62.2 | 58.9 | 61.6 | 65.7 | 49.9 | 58.2 |
HER2 − , ER − | 1.4 | 0.0 | 1.7 | 2.9 | 0.0 | 4.2 |
Chemotherapy received | ||||||
Taxane based therapy | 40.6 | 37.0 | 41.7 | 65.7 | 66.7 | 62.5 |
Anthracycline based therapy | 59.4 | 63.0 | 58.3 | 34.3 | 33.3 | 37.5 |
